▶ AOD-9604 · SUBTOPIC · MECHANISM
AOD-9604 Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Synthetic 15-amino-acid fragment of human growth hormone (residues 176-191). Retains the C-terminal lipolytic domain of HGH without the growth-promoting IGF-1 elevation. Drives beta-adrenergic fat oxidation; daily SQ at investigational doses.
PHARMACOKINETIC HALF-LIFE
Reported half-life for AOD-9604: Short (minutes) plasma. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
AOD-9604 is a defined sequence: 16-residue fragment corresponding to hGH(177-191) with N-terminal Tyrosine addition. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
AOD-9604 is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
Lipolysis is the breakdown of triglycerides in adipose tissue, driven by hormone-sensitive lipase activation downstream of cAMP elevation. GH-axis peptides (GH-axis reference) preferentially target visceral adipose. Glucagon-receptor agonism (the third arm of GLP-1) also drives hepatic lipid mobilization.
The growth hormone axis is regulated by two complementary upstream signals: GHRH (stimulatory, from the hypothalamus, acting on the GHRH receptor on pituitary somatotrophs) and ghrelin (stimulatory, from the stomach, acting on the GHS-R1a). Research peptides target both arms: GH-axis reference and CJC-1295 (GHRH analogs); ipamorelin, GHRP-6, and hexarelin (ghrelin-receptor agonists).
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
12-week Metabolic Pharmaceuticals Phase 2b at 1 mg/day did not meet primary weight-loss endpoint.
Veterinary and human cartilage research reported in registry data; not consistently in peer-reviewed Western journals.
MECHANISM Q+A
▶ How does AOD-9604 differ from full-length hGH?
AOD-9604 was designed to retain the lipolytic activity of hGH without engaging the growth-hormone receptor in a way that elevates IGF-1. In vitro, this design held; in vivo, it did not deliver the obesity outcomes anticipated.
CITED LITERATURE
- Heffernan M, et al.. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001. PMID 11713213. link
- Ng FM, et al.. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000. PMID 11146368. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19